Subpopulations

(absolute quantities)

Patients with RMS (favorable localization of the primary tumor)

Patients with RMS (unfavorable localization of the primary tumor)

Р

CD3+

19.5 ± 2.4 (n = 3)

6.4 ± 1.9 (n = 10)

0.006

CD3+ CD2+

29.5 ± 3.0 (n = 3)

9.5 ± 3.8 (n = 7)

0.013

CD3+ CD8+

16.3 ± 2.2 (n = 3)

5.4 ± 1.4 (n = 9)

0.003

CD5+

19.8 ± 2.5 (n = 3)

5.9 ± 2.0 (n = 9)

0.047

CD56+

3.4 ± 0.5 (n = 3)

0.8 ± 0.2 (n = 8)

0.000

CD19+ CD5+

16.2 ± 11.9 (n = 3)

0.8 ± 0.4 (n = 8)

0.044

αβTCR

24.9 ± 1.6 (n = 3)

8.2 ± 3.5 (n = 7)

0.018

γδTCR

4.1 ± 0.8 (n = 3)

1.3 ± 0.4 (n = 7)

0.005

CD8+ HLADR+

4.4 ± 1.6 (n = 2)

1.7 ± 0.3 (n = 7)

0.017